283 related articles for article (PubMed ID: 21933667)
1. Mineral-bone metabolism markers in young hemodialysis patients.
Osorio A; Ortega E; Torres JM; Sanchez P; Ruiz-Requena E
Clin Biochem; 2011 Dec; 44(17-18):1425-8. PubMed ID: 21933667
[TBL] [Abstract][Full Text] [Related]
2. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
3. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
4. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
[TBL] [Abstract][Full Text] [Related]
5. Biochemical markers of vascular calcification in elderly hemodialysis patients.
Osorio A; Ortega E; Torres JM; Sanchez P; Ruiz-Requena E
Mol Cell Biochem; 2013 Feb; 374(1-2):21-7. PubMed ID: 23124853
[TBL] [Abstract][Full Text] [Related]
6. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
[TBL] [Abstract][Full Text] [Related]
7. News on biomarkers in CKD-MBD.
Mazzaferro S; Tartaglione L; Rotondi S; Bover J; Goldsmith D; Pasquali M
Semin Nephrol; 2014 Nov; 34(6):598-611. PubMed ID: 25498379
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
[TBL] [Abstract][Full Text] [Related]
9. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
[TBL] [Abstract][Full Text] [Related]
10. Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis.
Nagata Y; Inaba M; Imanishi Y; Okazaki H; Yamada S; Mori K; Shoji S; Koyama H; Okuno S
Osteoporos Int; 2015 Mar; 26(3):1053-61. PubMed ID: 25403902
[TBL] [Abstract][Full Text] [Related]
11. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients].
Shiota J; Izumi N; Kasahara H; Tagawa H; Chiba T; Nihei H
Nihon Jinzo Gakkai Shi; 2010; 52(8):1022-8. PubMed ID: 21254698
[TBL] [Abstract][Full Text] [Related]
13. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
[TBL] [Abstract][Full Text] [Related]
14. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.
Bielesz BO; Hecking M; Plischke M; Cejka D; Kieweg H; Haas M; Marculescu R; Hörl WH; Bieglmayer C; Sunder-Plassmann G
Clin Biochem; 2014 Sep; 47(13-14):1316-9. PubMed ID: 24956265
[TBL] [Abstract][Full Text] [Related]
15. Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis.
Ambroszkiewicz J; Sands D; Gajewska J; Chelchowska M; Laskowska-Klita T
Adv Med Sci; 2013; 58(2):338-43. PubMed ID: 24277958
[TBL] [Abstract][Full Text] [Related]
16. Association between phosphate removal and markers of bone turnover in haemodialysis patients.
Albalate M; de la Piedra C; Fernández C; Lefort M; Santana H; Hernando P; Hernández J; Caramelo C
Nephrol Dial Transplant; 2006 Jun; 21(6):1626-32. PubMed ID: 16490746
[TBL] [Abstract][Full Text] [Related]
17. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
18. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.
Okuno S; Ishimura E; Tsuboniwa N; Norimine K; Yamakawa K; Yamakawa T; Shoji S; Mori K; Nishizawa Y; Inaba M
Osteoporos Int; 2013 Feb; 24(2):605-12. PubMed ID: 22581293
[TBL] [Abstract][Full Text] [Related]
19. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).
Sasaki N; Kusano E; Takahashi H; Ando Y; Yano K; Tsuda E; Asano Y
J Bone Miner Metab; 2005; 23(1):41-7. PubMed ID: 15616893
[TBL] [Abstract][Full Text] [Related]
20. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
